NO and PGI(2) in coronary endothelial dysfunction in transgenic mice with dilated cardiomyopathy

Basic Res Cardiol. 2008 Sep;103(5):417-30. doi: 10.1007/s00395-008-0723-2. Epub 2008 Apr 22.

Abstract

Objective: The aim of the present work was to analyze coronary endothelial function in the transgenic mouse model of dilated cardiomyopathy (Tgalphaq*44 mice).

Methods: Coronary vasodilatation, both NO-dependent (induced by bradykinin) and PGI(2)-dependent (induced by acetylcholine), was assessed in the isolated hearts of Tgalphaq*44 and FVB mice. Cardiac function was analyzed in vivo (MRI).

Results: In Tgalphaq*44 mice at the age of 2-4 months cardiac function was preserved and there were no alterations in endothelial function. By contrast, in Tgalphaq*44 mice at the age of 14-16 months cardiac function was significantly impaired and NO, but not PGI(2)-dependent coronary function was altered. Interestingly, the basal level of PGI(2) in coronary circulation increased fourfold as compared to FVB mice. Cardiac O(2) (-) production increased 1.5-fold and 3-fold in Tgalphaq*44 vs. FVB mice at the age of 2-6 and 14-16 months, respectively, and was inhibited by apocynin. Interestingly, inhibition of NADPH oxidase or NOS-3 normalized augmented PGI(2) production in Tgalphaq*44 mice. There was also an increased expression of gp91phox in Tgalphaq*44 vs. FVB hearts, without evident alterations in the expression of COX-1, COX-2, NOS-3 and PGI(2)-synthase.

Conclusions: In the mouse model of dilated cardiomyopathy, endothelial dysfunction in coronary circulation is present in the late but not the early stage of heart failure pathology and is characterized by a decrease in NO bioavailability and a compensatory increase in PGI(2). Both the decrease in NO activity and the increase in PGI(2) activity may result from excessive O(2) (-) production by cardiac NADPH oxidase in Tgalphaq*44 hearts.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / metabolism
  • Age Factors
  • Animals
  • Cardiomyopathy, Dilated / metabolism*
  • Coronary Artery Disease / metabolism*
  • Cyclooxygenase 1 / metabolism
  • Cyclooxygenase 2 / metabolism
  • Cytochrome P-450 Enzyme System / metabolism
  • Disease Models, Animal
  • Endothelium, Vascular / metabolism*
  • Epoprostenol / metabolism*
  • Heart Failure / metabolism
  • Intramolecular Oxidoreductases / metabolism
  • Membrane Proteins / metabolism
  • Mice
  • Mice, Inbred Strains
  • Mice, Transgenic
  • Myocardium / metabolism
  • NADPH Oxidases / metabolism
  • Nitric Oxide / metabolism*
  • Nitric Oxide Synthase Type II / metabolism
  • Nitric Oxide Synthase Type III
  • Superoxides / metabolism
  • Vasodilation / physiology

Substances

  • Membrane Proteins
  • Superoxides
  • Nitric Oxide
  • 6-Ketoprostaglandin F1 alpha
  • Cytochrome P-450 Enzyme System
  • Epoprostenol
  • Nitric Oxide Synthase Type II
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • Ptgs2 protein, mouse
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Ptgs1 protein, mouse
  • NADPH Oxidases
  • Intramolecular Oxidoreductases
  • prostacyclin synthetase